RE: Re rate8 Dec 2021 17:15
9th August RMS
Dr Tim Mitchell, CEO of Sareum Holdings plc, said: "This new subscription is Sareum's fourth since 1 June this year, reflecting the strong and continuing interest in our proprietary TYK2/JAK1 development programmes in autoimmune diseases, including the immune overreaction to Covid-19, and cancer. With the funds raised during this period now totalling over £4.5 million, our financial position has been significantly strengthened and we are looking forward to completing the preclinical studies with SDC-1801 and advancing it into clinical development, and to progressing the preclinical development of our second TYK2/JAK1 inhibitor SDC-1802.
Just release the results! They obviously have them! Pecuniary advantage!?
1802 similar to 1801 so as proported it's progress is similar.
Not fussed if no likes here. I'm dealing with facts.
We are holding gold. Getting boring.